In development: Guidance, quality standards and advice

Skip to filters Skip to results

Showing 51 to 100 of 294

Sort by

Guidance programme: Technology appraisal guidance`Remove $Guidance programme: Technology appraisal guidance filter`

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Cemiplimab for treating recurrent or metastatic cervical cancer that has progressed on or after platinum-based chemotherapy (review of TA901) [ID6610]	Technology appraisal guidance	3 September 2026
Ceralasertib with durvalumab for treating advanced non-small-cell lung cancer after antiPD-L1 treatment and platinum-based chemotherapy [ID6612]	Technology appraisal guidance	TBC
Ciltacabtagene autoleucel for treating relapsed and lenalidomide-refractory multiple myeloma after 1 to 3 therapies [ID4012]	Technology appraisal guidance	TBC
Cimavax for treating wild-type EGFR-positive non-small-cell lung cancer [ID1259]	Technology appraisal guidance	TBC
Cobolimab with dostarlimab and docetaxel for treating advanced non-small-cell lung cancer after anti-PD-L1 treatment and chemotherapy [ID6398]	Technology appraisal guidance	TBC
Cositecan for treating platinum or taxane resistant advanced, mucinous, epithelial ovarian cancer [ID826]	Technology appraisal guidance	TBC
Daprodustat for treating anaemia in people with chronic kidney disease [ID3987]	Technology appraisal guidance	TBC
Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable [ID3843]	Technology appraisal guidance	13 May 2026
Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when an autologous stem cell transplant is suitable [ID6249]	Technology appraisal guidance	13 May 2026
Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia in children and adults [ID1297]	Technology appraisal guidance	28 July 2021
Datopotamab deruxtecan for previously treated hormone receptor-positive HER2-negative unresectable or metastatic breast cancer [ID6348]	Technology appraisal guidance	TBC
DCVax-L for treating glioblastoma [ID836]	Technology appraisal guidance	TBC
Decitabine–cedazuridine with venetoclax for untreated acute myeloid leukaemia when intensive induction chemotherapy is unsuitable [ID6601]	Technology appraisal guidance	24 March 2027
Degarelix before or with radiotherapy for treating high-risk localised and locally advanced hormone-dependent prostate cancer [ID6419]	Technology appraisal guidance	TBC
Denecimig (Mim8) for preventing bleeding episodes in haemophilia A in people of any age [ID6400]	Technology appraisal guidance	24 February 2027
Depemokimab for treating severe eosinophilic asthma in people 12 years and over [ID6447]	Technology appraisal guidance	TBC
Deuruxolitinib for treating severe alopecia areata [ID6597]	Technology appraisal guidance	8 October 2026
Deutetrabenazine for treating tardive dyskinesia [ID6550]	Technology appraisal guidance	TBC
Dexmedetomidine for treating agitation associated with bipolar disorder in people 18 to 75 years [TSID10725]	Technology appraisal guidance	TBC
Dexmedetomidine for treating agitation associated with schizophrenia [TSID10726]	Technology appraisal guidance	TBC
Domvanalimab with zimberelimab for untreated unresectable advanced gastric, gastro-oesophageal junction or oesophageal cancer [ID6606]	Technology appraisal guidance	TBC
Donanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID6222]	Technology appraisal guidance	TBC
Donidalorsen for preventing recurrent attacks of hereditary angioedema in people 12 years and over [ID6457]	Technology appraisal guidance	18 June 2026
Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency (MA review of TA779) [ID6326]	Technology appraisal guidance	23 July 2026
Dostarlimab with chemotherapy for untreated and with niraparib for maintenance treatment of advanced non-mucinous epithelial ovarian, fallopian tube or primary peritoneal cancer [ID6311]	Technology appraisal guidance	TBC
Dostarlimab with docetaxel for treating advanced non-small-cell lung cancer after anti-PD-L1 treatment and chemotherapy [ID6530]	Technology appraisal guidance	TBC
Doxorubicin nanoparticles for previously treated advanced hepatocellular carcinoma [ID1314]	Technology appraisal guidance	TBC
Dupilumab for treating chronic spontaneous urticaria in people 12 years and over [ID4055]	Technology appraisal guidance	TBC
Durvalumab in combination for neoadjuvant and adjuvant treatment of resectable gastric and gastro-oesophageal junction cancer [ID6374]	Technology appraisal guidance	TBC
Durvalumab with platinum-based chemotherapy, then with or without olaparib, for treating newly diagnosed advanced or recurrent endometrial cancer [ID6317]	Technology appraisal guidance	TBC
Durvalumab with tremelimumab for treating limited-stage small-cell lung cancer after chemoradiation [ID5097]	Technology appraisal guidance	TBC
Efgartigimod with recombinant human hyaluronidase PH20 for treating chronic inflammatory demyelinating polyneuropathy [ID6409]	Technology appraisal guidance	29 July 2026
Eflornithine for treating high-risk neuroblastoma with complete or partial response after immunotherapy [ID4060]	Technology appraisal guidance	TBC
Elamipretide for treating Barth syndrome in people of any age [ID6545]	Technology appraisal guidance	TBC
Elexacaftor–tezacaftor–ivacaftor with ivacaftor for treating cystic fibrosis without an F508del mutation and with a mutation in the CFTR gene that is responsive to elexacaftor–tezacaftor–ivacaftor in people aged 6 and over [TSID11847]	Technology appraisal guidance	TBC
Encorafenib with binimetinib for treating BRAF V600E mutation-positive advanced non-small-cell lung cancer [ID6177]	Technology appraisal guidance	TBC
Enfortumab vedotin for treating locally advanced or metastatic urothelial cancer after 2 therapies [ID3845]	Technology appraisal guidance	15 June 2022
Epcoritamab with rituximab and lenalidomide for treating relapsed or refractory follicular lymphoma after 1 or more systemic treatments [ID6586]	Technology appraisal guidance	3 September 2026
ERC1671 for treating progressed or recurrent grade IV glioma (glioblastoma or gliosarcoma) [ID1623]	Technology appraisal guidance	TBC
Etripamil for treating paroxysmal supraventricular tachycardia [ID6581]	Technology appraisal guidance	TBC
Evolocumab for preventing major cardiovascular events in people aged 50 to 79 at high risk who have not had a myocardial infarction or stroke [TSID11920]	Technology appraisal guidance	TBC
Fezolinetant for treating vasomotor symptoms associated with the menopause [ID5071]	Technology appraisal guidance	31 March 2026
Fidanacogene elaparvovec for treating moderately severe to severe haemophilia B [ID4032]	Technology appraisal guidance	TBC
Fidrisertib for reducing heterotopic ossification caused by fibrodysplasia ossificans progressiva in people 5 years and over [ID6678]	Technology appraisal guidance	TBC
Filgotinib for treating axial spondyloarthritis [ID6594]	Technology appraisal guidance	TBC
Finerenone for treating heart failure with preserved or mildly reduced ejection fraction [ID6514]	Technology appraisal guidance	TBC
Ganaxolone for adjunctive treatment of epilepsy associated with tuberous sclerosis complex with CDKL5 deficiency disorder [TSID12126]	Technology appraisal guidance	TBC
Gantenerumab for treating early Alzheimer's disease [ID6142]	Technology appraisal guidance	TBC
Gefurulimab for treating antibody-positive generalised myasthenia gravis [TSID12256]	Technology appraisal guidance	TBC
Givinostat for treating Duchenne muscular dystrophy in people 6 years and over [ID6323]	Technology appraisal guidance	TBC

Results per page

10
25
50
All